Last Update 24 Feb 26

Fair value Increased 5.77%

BHC: Affordable Medicines Positioning Will Support Value Despite RED C And Separation Uncertainty

Analysts have lifted their Bausch Health Companies price target to $7.86 from $7.43. This reflects updated views on revenue trends, margins, and future P/E following recent research that highlights both opportunities in affordable medicines and ongoing uncertainty around the full separation from Bausch + Lomb.

Analyst Commentary

Recent research around Bausch Health and Bausch + Lomb gives you a mixed picture, with some analysts seeing potential upside tied to affordable medicines and others focused on execution risks around product performance and the separation process.

Bullish Takeaways

Bullish analysts point to the affordable medicines theme as a key support for Bausch Health, viewing this positioning as helpful for sustaining demand and supporting the higher price target of US$8.
The raised target for Bausch Health, alongside the higher Bausch + Lomb target to US$15, suggests some optimism that the group can execute on its portfolio and maintain earnings power as the separation plays out.
The 2% Q4 revenue beat at Bausch + Lomb is seen as a positive data point, giving bulls some comfort that the eye care business is holding up against expectations, which can be supportive for the overall valuation of Bausch Health.
Expectations for contact lens market growth of 4.5% or better in 2026 are viewed by supportive analysts as a tailwind for Bausch + Lomb, which could indirectly help sentiment around Bausch Health if the separation is resolved cleanly.

Bearish Takeaways

Bearish analysts keep cautious ratings on Bausch + Lomb even with the higher target, highlighting that uncertainty around the full separation from Bausch Health continues to weigh on how they value both entities.
Concerns around clinical or product setbacks, such as the RED C outcome cited by Truist, increase the pressure ahead of the Xifaxan loss of exclusivity, which can limit confidence in Bausch Health's future cash flow profile.
Some analysts see the raised targets as largely reflecting updated models rather than a clear change in conviction, so they retain neutral or cautious stances on execution and capital allocation.
Unclear timing and structure for the full separation creates an overhang in the eyes of more cautious analysts, who see this as a key reason to apply more conservative assumptions to Bausch Health's valuation and P/E.

What’s in the News

Bausch Health and its dental business OraPharma marked the 25th anniversary of ARESTIN, a locally administered antibiotic used with scaling and root planing for adult periodontitis. They state it is the only FDA approved locally applied antibiotic for this indication, supported by over two decades of clinical use (company announcement).
The company reported a goodwill impairment of $145 million for the fourth quarter ended December 31, 2025, which affects the carrying value of certain assets on its balance sheet (company announcement).
Bausch Health issued full year 2026 revenue guidance in a range of US$10.625b to US$10.875b, providing a reference point for how management currently frames expected business activity (company guidance).
Results from the global Phase 3 RED C program in adults with liver cirrhosis showed that amorphous rifaximin solid soluble dispersion did not meet the primary endpoint for preventing hepatic encephalopathy. The treatment was described as safe and well tolerated, and the company reiterated its focus on future hepatology treatments (company announcement).

Valuation Changes

Fair Value: updated to $7.86 from $7.43, a modest increase in the modeled equity value per share.
Discount Rate: held steady at 11.87%, so the required return assumption for valuing future cash flows is unchanged.
Revenue Growth: shifted from a 1.10% decline to a 1.96% decline, indicating a slightly weaker revenue trajectory is now embedded in the model.
Net Profit Margin: adjusted from 4.21% to 3.74%, reflecting a more conservative view on profitability.
Future P/E: raised from 9.62x to 11.33x, implying a higher valuation multiple applied to expected earnings.

18 views

Key Takeaways

Strategic acquisitions and late-stage drug development position the company to benefit from rising chronic disease rates and expanding healthcare access globally.
Strong operating performance, ongoing deleveraging, and digital sales initiatives improve financial stability, operating margins, and long-term growth prospects.
Dependence on a few key products, regulatory pricing pressures, and heavy debt burden create significant risks to revenue stability, profitability, and future growth opportunities.

Catalysts

About Bausch Health Companies

Operates as a diversified specialty pharmaceutical and medical device company, develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, generic pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health in the United States and internationally.What are the underlying business or industry changes driving this perspective?

Bausch's initiatives to expand in gastroenterology and hepatology, notably through the acquisition of DURECT and ongoing late-stage pipeline development (e.g., SSD rifaximin Phase III), position the company to capitalize on rising chronic disease rates and aging populations-potentially driving future revenue growth.
International diversification, with sustained double-digit growth in regions like EMEA and Canada and new product launches in Latin America and Poland, enables Bausch to benefit from expanding healthcare access in emerging markets-supporting long-term topline growth and reducing geographic concentration risk.
Strong recent performance in branded generics and specialty pharmaceuticals, including double-digit Salix and Solta revenue growth and positive trends for promoted Canadian products, indicates the company is well-placed to capture demand for affordable treatments-improving operating leverage and margins.
Continuing progress in debt reduction (e.g., $7.9B refinancing, repayment of high-interest notes and accounts receivable facility) and focus on deleveraging are set to lower interest expenses and strengthen net earnings-reducing financial risk over time.
Accelerating operational excellence via AI-based sales tools for patient adherence and targeted promotional investments (notably for Xifaxan and Solta) enhances salesforce effectiveness and patient retention-supporting sustained volume growth and improved margins.

Bausch Health Companies Earnings and Revenue Growth

Bausch Health Companies Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming Bausch Health Companies's revenue will decrease by 0.9% annually over the next 3 years.
Analysts assume that profit margins will increase from 1.0% today to 2.6% in 3 years time.
Analysts expect earnings to reach $264.4 million (and earnings per share of $3.19) by about September 2028, up from $98.0 million today.
In order for the above numbers to justify the analysts price target, the company would need to trade at a PE ratio of 13.9x on those 2028 earnings, down from 27.7x today. This future PE is lower than the current PE for the US Pharmaceuticals industry at 19.5x.
Analysts expect the number of shares outstanding to grow by 0.54% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 11.5%, as per the Simply Wall St company report.

Bausch Health Companies Future Earnings Per Share Growth

Risks

What could happen that would invalidate this narrative?

The inclusion of Xifaxan in the U.S. Medicare Drug Price Negotiation program (IRA) is likely to result in significant price cuts (potentially 40–80%) by 2027, directly compressing Bausch Health's revenue and net margins from its largest product franchise.
High industry exposure to government and regulatory scrutiny on drug pricing globally presents sustained risk that cannot be offset by internal strategies, threatening both top-line growth and profitability in core markets.
Heavy reliance on a small number of growth drivers-especially Xifaxan and Salix segment products-exposes the company to concentration risk and potential revenue declines should these products face patent cliffs, generic entry, or market headwinds.
Elevated leverage remains a persistent risk, as Bausch Health carries ~$16.1 billion in gross debt; while refinancing and deleveraging efforts are ongoing, high interest expense continues to pressure net earnings and limits flexibility for M&A or R&D investment.
The company's growth-through-acquisition strategy introduces execution and pipeline risk, particularly as recently announced deals (like DURECT) involve clinical assets that have failed to meet primary endpoints in Phase II, creating long-term uncertainty for future revenue streams and earnings.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of $7.083 for Bausch Health Companies based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $10.0, and the most bearish reporting a price target of just $5.0.
In order for you to agree with the analyst's consensus, you'd need to believe that by 2028, revenues will be $10.1 billion, earnings will come to $264.4 million, and it would be trading on a PE ratio of 13.9x, assuming you use a discount rate of 11.5%.
Given the current share price of $7.35, the analyst price target of $7.08 is 3.8% lower. The relatively low difference between the current share price and the analyst consensus price target indicates that they believe on average, the company is fairly priced.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Bausch Health Companies?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Gastroenterology Expansion And Global Markets Will Unlock Opportunities